Results 1 to 10 of about 3,643 (112)

Non-Competitive AMPA Receptor Antagonist Perampanel Inhibits Ischemia-Induced Neurodegeneration and Behavioral Deficits in Focal Cortical Pial Vessel Disruption Stroke Model [PDF]

Cells
Glutamate receptors represent a potential target for neuroprotection in neurodegenerative neurological conditions. Perampanel, a non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor (AMPAR) antagonist, is clinically approved for the
Michael G. Zaki, Mohamed Taha Moutaoufik, Mahboubeh Pordeli, Mohan Babu, Changiz Taghibiglou, Francisco S. Cayabyab   +5 more
doaj   +2 more sources

Treatment with perampanel alleviates depression-like behavior in mice via modulating GluN2B expression to improve excitatory synaptic transmission [PDF]

Translational Psychiatry
Antidepressants that target the glutamatergic system, such as ketamine, have shown promising results. However, the contribution of other potential medications targeting the glutamate system to depression is unclear. Our research found that perampanel can
Jin-Ming Liu, Yan-Lin Zhang, Fang Guo, Bin-Wu Li, Hu Chen, Yuye Mo, Jiangwei Kong, Xiaohui Tan, Weibin Wu, Xiong Cao   +9 more
doaj   +2 more sources

The real-world safety of lacosamide and perampanel in children: a disproportionality analysis of the FDA Adverse Event Reporting System [PDF]

Therapeutic Advances in Drug Safety
Background: Lacosamide and perampanel are two novel antiepileptic drugs with distinct mechanisms of action. However, the real-world evidence of adverse events (AEs) related to these drugs in children is limited. Objectives: This study aims to explore the
Yani Tan, Cuilin Li, Qin Yi, Xin Liu, Yuping Yang, Lian Zheng, Long Wei, Li Huang   +7 more
doaj   +2 more sources

Perampanel Regulates Neuroinflammation and Ferroptosis via Activating FSP1 Following Brain Ischemia [PDF]

Journal of Inflammation Research
Jian-Meng Lv, Ya-Juan Pan, Xuan Wang, Mei-Mei Zhang, Wei Li, Juan Liu, Tao Wang Department of Neurology, Shaanxi Provincial People’s Hospital, Xi’an, Shaanxi, 710068, People’s Republic of ChinaCorrespondence: Tao Wang, Department of Neurology, Shaanxi ...
Lv JM, Pan YJ, Wang X, Zhang MM, Li W, Liu J, Wang T   +6 more
doaj   +2 more sources

Optimal Use of Perampanel in Asian Patients with Epilepsy: Expert Opinion

Therapeutics and Clinical Risk Management, 2021
Yotin Chinvarun,1 Chin-Wei Huang,2 Ye Wu,3 Hsiu-Fen Lee,4 Surachai Likasitwattanakul,5 Jing Ding,6 Takamichi Yamamoto7 1Department of Neurology, Phramongkutklao Royal Army Hospital and Medical College, Bangkok, Thailand; 2Department of Neurology ...
Yotin Chinvarun, Chin-Wei Huang, Hsiu-Fen Lee   +2 more
exaly   +2 more sources

Efficacy and safety of perampanel as first adjunctive therapy in patients with focal‐onset seizures or generalized tonic‐clonic seizures in four post‐marketing studies across regions [PDF]

Epilepsia Open
Objective Early response to anti‐seizure medication (ASM) is associated with a favorable prognosis in patients with epilepsy. Research is required to confirm existing data on the clinical use of perampanel as first adjunctive therapy in different patient
Stefano Meletti, Vineet Punia, Amitabh Dash, Anna Lisa Gentile, Ricardo Sáinz‐Fuertes, Samantha Goldman, Tobias Goldmann, Anna Patten, Dinesh Kumar, Leock Y. Ngo, Bernhard J. Steinhoff   +10 more
doaj   +2 more sources

Adjunctive perampanel for glioma-associated epilepsy

Epilepsy & Behavior Case Reports, 2018
Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that perampanel, an amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist, would treat glioma-related epilepsy.
Sarah Woodring, Eric S Lipp, James E Herndon   +2 more
exaly   +3 more sources

Preliminary Safety Study of a Single-dose Perampanel Drip Infusion in Brain Tumor Patients to Prevent Early Postoperative Seizures: The poSTOP Seizure-1 SF Study [PDF]

Neurologia Medico-Chirurgica
Early postoperative seizures, defined as occurring within 7 days after surgery, are a significant complication that occurs following neurosurgical procedures involving cerebral manipulation.
Narushi SUGII, Kota ARAKI, Eiichi ISHIKAWA   +2 more
doaj   +2 more sources

Intravenous perampanel as an alternative to the oral formulations in Japanese patients with epilepsy

Epilepsia Open, 2023
Objective Perampanel is an oral anti‐seizure medication, which is approved in Japan for focal‐onset seizures, with/without focal to bilateral tonic–clonic seizures, as monotherapy/adjunctive therapy in patients aged 4 years and older.
Ryosuke Hanaya, Yuichi Kubota, Masahiro Mizobuchi, Koji Iida, Tomonori Ono, Hiromichi Motooka, Naoki Nakano, Ayataka Fujimoto, Masaki Iwasaki, Masafumi Fukuda, Akihiko Kondo, Katsuhisa Uruno, Shintaro Yamamuro, Kohei Yamaguchi, Kisaki Onishi, Leock Y Ngo, Yushi Inoue   +16 more
doaj   +1 more source

Real‐world analysis of hospitalizations in patients with epilepsy and treated with perampanel

Epilepsia Open, 2021
Objectives (1) To evaluate risk of hospitalization following initiation of perampanel (pre‐ and post‐analysis) and (2) to compare hospitalization rates following initiation of perampanel vs lacosamide.
Edward Faught, Xuan Li, Jiyoon Choi, Manoj Malhotra, Russell L. Knoth   +4 more
doaj   +1 more source